Financial Contrast: Anavex Life Sciences (NASDAQ:AVXL) vs. Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio (NASDAQ:TVGN) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Tevogen Bio and Anavex Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	0	0	1	0	3.00
Anavex Life Sciences	0	0	1	1	3.50

Tevogen Bio presently has a consensus target price of $4.20, indicating a potential upside of 479.23%. Anavex Life Sciences has a consensus target price of $40.00, indicating a potential upside of 547.77%. Given Anavex Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Tevogen Bio.

Insider & Institutional Ownership

31.5% of Anavex Life Sciences shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Tevogen Bio and Anavex Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	-273.73%	229.30%
Anavex Life Sciences	N/A	-29.04%	-26.85%

Earnings & Valuation

This table compares Tevogen Bio and Anavex Life Sciences’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A
Anavex Life Sciences	N/A	N/A	-$47.51 million	($0.50)	-12.35

Risk & Volatility

Tevogen Bio has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

Anavex Life Sciences beats Tevogen Bio on 6 of the 9 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.